

available at www.sciencedirect.com



www.elsevier.com/locate/brainres

BRAIN RESEARCH

Research Report

PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah^{enu2} mice

Jennifer E. Embury^{a,*}, Catherine E. Charron^e, Anatoly Martynyuk^b, Andreas G. Zori^a, Bin Liu^c, Syed F. Ali^f, Neil E. Rowland^d, Philip J. Laipis^a

ARTICLEINFO

Article history:
Accepted 23 September 2006
Available online 15 November 2006

Keywords:
Phenylketonuria
Oxidative stress
Monoamines
Gene therapy
Adeno-associated virus

ABSTRACT

Phenylketonuria (PKU) is a common genetic disorder in humans that arises from deficient activity of phenylalanine hydroxylase (PAH), which catalyzes the conversion of phenylalanine to tyrosine. There is a resultant hyperphenylalanemia with subsequent impairment in cognitive abilities, executive functions and motor coordination. The neuropathogenesis of the disease has not been completely elucidated, however, oxidative stress is considered to be a key feature of the disease process. Hyperphenylalanemia also adversely affects monoaminergic metabolism in the brain. For this reason we chose to evaluate the nigrostriatum of Pahenu2 mice, to determine if alterations of monoamine metabolism resulted in morphologic nigrostriatal pathology. Furthermore, we believe that recent developments in adeno-associated virus (AAV)-based vectors have greatly increased the potential for long-term gene therapy and may be a viable alternative to dietary treatment for this metabolic disorder. In this study we identified neurodegenerative changes with regenerative responses in the nigrostriatum of Pahenu2 mice that are consistent with oxidative injury and occurred as early as 4 weeks of age. These neuropathologic changes were reversed following portal vein delivery of a recombinant adeno-associated virus-mouse phenylalanine hydroxylase-woodchuck hepatitis virus posttranscriptional response element (rAAV-mPAH-WPRE) vector to Pahenu2 mice and corresponded to rapid reduction of serum Phe levels.

© 2006 Elsevier B.V. All rights reserved.

^aDepartment of Biochemistry and Molecular Biology, PO Box 100245, College of Medicine, University of Florida, Gainesville, FL 32610, USA

^bDepartment of Anesthesiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA

^cDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA

^dDepartment of Psychology, College of Liberal of Arts and Sciences, University of Florida, Gainesville, FL 32610, USA

^eNational Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom

^fNeurochemistry Laboratory, National Center for Toxicology Research/FDA, Jefferson, AR 72079, USA

^{*} Corresponding author. Fax: +1 352 392 1445. E-mail address: jembury@ufl.edu (J.E. Embury).

Abbreviations:

AAV, adeno-associated virus BDNF, brain-derived neurotrophic factor CX, cortex DA, dopamine DAB, 3,3'-diaminobenzidine tetrachloride DOPAC, 3,4-dihydroxy-phenylacetic acid GFAP, glial fibrillary acidic protein H₂0₂, hydrogen peroxidase 5-HIAA, 5-hydroxyindoleacetic acid 5-HT, 5-hydroxytryptamine (serotonin) HPA, hyperphenylalanemia HVA, homovanillic acid INOS, inducible nitric oxide synthase MPTP. 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine PAH, phenylalanine hydroxylase PD. Parkinson's disease PKU, phenylketonuria PHE, phenylalanine rAAV-mPAH-WPRE, recombinant

SNPc, substantia nigra pars compacta STR, striatal TH, tyrosine hydroxylase

adeno-associated virus-mouse

hydroxylase-woodchuck hepatitis virus post transcriptional response

TYR, tyrosine

phenylalanine

RS, reactive species SN, substantia nigra

element

VTA, ventral tegmental area

1. Introduction

Phenylketonuria (PKU) is a disorder of amino acid metabolism caused by a deficiency of hepatic phenylalanine hydroxylase (PAH) activity. Under these conditions, phenylalanine (Phe) is unable to be converted to tyrosine (Tyr), which results in millimolar concentrations of serum Phe. The increased Phe is subsequently metabolized to the organic acid ketones phenylpyruvate, phenylacetate, and phenylactate. The disease manifests itself primarily as a neurologic disorder, and if untreated, can result in microcephaly, mental retardation, epilepsy, and progression of motor disorders in the second or third decade. The treatment is difficult to implement and consists of lifetime dietary restriction of phenylalanine (Krause et al., 1985; Scriver, 1995; Smith and Wolff, 1974).

The etiology of the neurologic disease process in PKU patients has not been fully elucidated but is thought to occur secondarily to increased concentrations of phenylalanine in the blood. One factor that is considered to play a

role in the neuropathogenesis of the disease is oxidative stress. The role of oxidative damage in the neuropathology of organic acidurias is presented in a review by Wajner et al. (2004) who discusses considerable evidence in which organic acid accumulation associated with various metabolic disorders will induce free radical and reactive species (RS) generation and will also decrease antioxidant defenses in tissues. These reactive species can inhibit various complexes of the respiratory chain and critical enzymes necessary for energy production resulting in metabolic failure, cell injury and cell death (Castro et al., 1994, 1998; Radi et al., 2002; Wyse et al., 2001). Free radicals also provoke cell injury and death directly by breaking cell lipid membranes, destroying proteins, and oxidizing DNA (Halliwell, 2001; Halliwell and Gutteridge, 1989a). In some of these disorders, the toxic metabolites were thought to be organic acids such as the phenylketones in PKU (Huttenlocher, 2000).

Hyperphenylalanemia (HPA) of PKU also results in the disruption of amino acid transport and metabolic pathways

Download English Version:

https://daneshyari.com/en/article/4331863

Download Persian Version:

https://daneshyari.com/article/4331863

<u>Daneshyari.com</u>